ClinicalTrials.gg

Program

Iparomlimab/Tuvonralimab

Also written as “QL1706”, “QL1706 injection” and “QL1706, IV infusion”.

Its studies are mostly in Uterine Cervical Neoplasms · Colorectal Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 3, since Jun 28, 202222 company-led studies, 14 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical2214 open or runningphase 3since Jun 28, 2022Jun 4, 2019Jun 2027phase 2 · NCT07272590

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Jun 4, 2019.

  1. Aug 1, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05487391 · 632 planned · China
  2. Sep 20, 2022Phase 2 study in Uterine Cervical NeoplasmsNCT05557565 · 150 enrolled · China
  3. Sep 30, 2022Phase 3 study in Nasopharyngeal CarcinomaNCT05576272 · 460 enrolled · China
  4. Oct 21, 2022Phase 2 study in Advanced Liver CancerNCT05603039 · 80 enrolled · China
  5. Jan 10, 2023Phase 3 study in Lung NeoplasmsNCT05690945 · 606 enrolled · China
  6. Mar 23, 2023Phase 2 study in Colorectal NeoplasmsNCT05799820 · 60 planned · China
  7. Jul 28, 2023Phase 3 study in Carcinoma, HepatocellularNCT05976568 · 668 planned · China
  8. Jun 1, 2024Phase 2 study in Advanced Solid TumorNCT06446388 · 360 planned · China
  9. Nov 11, 2024Phase 3 study in Colonic NeoplasmsNCT06686576 · 363 planned · China
  10. Jan 17, 2025Phase 3 study in Small Cell Lung CarcinomaNCT06789796 · 636 planned
  11. Feb 20, 2025Phase 2 study in Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNCT06852456 · 30 planned
  12. Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
  13. Jun 9, 2025Phase 3 study in Colorectal NeoplasmsNCT07025239 · 430 planned
  14. Nov 26, 2025Phase 2 study in Metastatic Solid TumorsNCT07272590 · 290 planned

Ahead

  1. Jun 2027Primary completion: phase 2 study in Metastatic Solid TumorsNCT07272590
  2. Aug 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05487391
  3. Sep 1, 2027Primary completion: phase 3 study in Carcinoma, HepatocellularNCT05976568
  4. Mar 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06789796

TargetBeta

CTLA4 →PDCD1 →read by rule
“A mixture of the two engineered monoclonal antibodies iparomlimab, which is an immunoglobulin G4 (IgG4) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and tuvonralimab, which is an IgG1 monoclonal anti”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cadonilimabruleAkesophase 345
volrustomigAstraZenecaphase 319
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07272590Metastatic Solid Tumors2Not yet recruitingJun 2027290
NCT07025239Colorectal Neoplasms3Not yet recruitingJul 2028430
NCT06949761Solid Tumor2Not yet recruitingSep 2026240
NCT06852456Resectable Locally Advanced Esophageal Squamous Cell Carcinoma2Not yet recruitingDec 203030
NCT06789796Small Cell Lung Carcinoma3Not yet recruitingMar 2028636
NCT06686576Colonic Neoplasms · China3RecruitingDec 2030363
NCT06446388Advanced Solid Tumor · China2Not yet recruitingJun 30, 2026360
NCT05976568Carcinoma, Hepatocellular · China3Not yet recruitingSep 1, 2027668
NCT05799820Colorectal Neoplasms · China2RecruitingMar 30, 202460
NCT05690945Lung Neoplasms · China3Active, not recruitingJun 2029606
NCT05603039Advanced Liver Cancer · China2UNKNOWNDec 30, 202380
NCT05576272Nasopharyngeal Carcinoma · China3Active, not recruitingDec 30, 2024460
NCT05557565Uterine Cervical Neoplasms · China2UNKNOWNOct 30, 2022150
NCT05487391Carcinoma, Non-Small-Cell Lung · China3RecruitingAug 31, 2027632
NCT05446883Uterine Cervical Neoplasms · China3RecruitingSep 1, 2024498
NCT05329025Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingJan 1, 2024100
NCT05309629Small Cell Lung Carcinoma · China2CompletedFeb 1, 202340
NCT05262413Advanced Renal Cell Carcinoma2UNKNOWNJul 30, 202360
NCT05179317Uterine Cervical Neoplasms · China2UNKNOWNDec 202260
NCT05171790Advanced Solid Tumors · China1UNKNOWNDec 31, 2021419
NCT04296994Advanced Malignant Tumor · China1UNKNOWNDec 31, 202199
NCT03986606Neoplasms · United States1UNKNOWNFeb 28, 202164

How it is read

Names in the registry

  • “QL1706”, 14 entries
  • “QL1706 injection”, 2 entries
  • “QL1706, IV infusion”, 1 entry
  • “QLC1101+QL1706”, 1 entry
  • “Iparomlimab and Tuvonralimab (QL1706)Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.